Fig. 1. Schematic of proposed surveillance scheme based on EAU guidelines during the COVID-19 pandemic within 12 months of transurethral resection.

Hypothetical time points for urine biomarker testing are highlighted, alongside biomarker-stratified cystoscopy or imaging in the context of an abnormal urine biomarker test. EAU, European Association of Urology; NMIBC, non-muscle-invasive bladder cancer.